FIGURE 4 from Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity
Year: 2023
Type: other
Abstract: CD62 L downregulation in CD8+ leukocytes from treated (Tumor 1) and untreated (Tumor 2) subcutaneous tumors caused by TAA-specific T cells and/or Delta-24-RGDOX. Leukocytes from the tumors in the treatment groups, as depicted in Fig. 3A, were profiled with flow cytometry. Representative flow cytometry histograms showing CD62 L expression on CD8+ leukocytes (A, left), endogenous OVA-specific CTLs (A, right, CD8+ OVA-Tet+) and pmel-1 T cells (B) from tumors of the indicated treatment groups. C, Quantification of the mean fluorescence intensity (MFI) of CD62 L on the cells mentioned in A and B. Leukocytes were from grouped tissue (4 to 7 mice/group) and processed in triplicate. The columns in the graphs represent the mean ± SD (n = 3). RGDOX: Delta-24-RGDOX; T cells: pmel-1 T cells. ns, not significant (P > 0.05); *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Two-tailed Student t test.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4382240671